These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29204337)

  • 1. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.
    Hilton JF; Clemons M; Pond G; Zhao H; Mazzarello S; Vandermeer L; Addison CL
    J Bone Oncol; 2018 Mar; 10():6-13. PubMed ID: 29204337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
    Addison CL; Bouganim N; Hilton J; Vandermeer L; Dent S; Amir E; Hopkins S; Kuchuk I; Segal R; Song X; Gertler S; Mazzarello S; Dranitsaris G; Ooi D; Pond G; Clemons M
    Breast Cancer Res Treat; 2014 Apr; 144(3):615-24. PubMed ID: 24638849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
    Hortobagyi GN; Van Poznak C; Harker WG; Gradishar WJ; Chew H; Dakhil SR; Haley BB; Sauter N; Mohanlal R; Zheng M; Lipton A
    JAMA Oncol; 2017 Jul; 3(7):906-912. PubMed ID: 28125763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
    Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.
    Addison CL; Pond GR; Zhao H; Mazzarello S; Vandermeer L; Goldstein R; Amir E; Clemons M
    Springerplus; 2014; 3():577. PubMed ID: 25332877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.
    Hadji P; Ziller M; Maurer T; Autenrieth M; Muth M; Ruebel A; May C; Birkholz K; Diebel E; Gleissner J; Rothe P; Gschwend JE
    J Bone Oncol; 2012 Dec; 1(3):88-94. PubMed ID: 26909262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
    Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
    Addison CL; Pond GR; Cochrane B; Zhao H; Chia SK; Levine MN; Clemons M
    J Bone Oncol; 2015 Jun; 4(2):47-53. PubMed ID: 26579488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
    Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
    Trinkaus M; Simmons C; Myers J; Dranatisaris G; Clemons M
    Support Care Cancer; 2010 Feb; 18(2):197-203. PubMed ID: 19424729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
    Barnadas A; Manso L; de la Piedra C; Meseguer C; Crespo C; Gómez P; Calvo L; Martinez P; Ruiz-Borrego M; Perelló A; Antón A; Codes M; Margelí M; Murias A; Salvador J; Seguí MÁ; de Juan A; Gavilá J; Luque M; Pérez D; Zamora P; Arizcuma A; Chacón JI; Heras L; Martin-Fernández M; Mahillo-Fernández I; Tusquets I
    Bone; 2014 Nov; 68():32-40. PubMed ID: 25108081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
    J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
    Miyashita H; Cruz C; Malamud S
    Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
    Clemons M; Dranitsaris G; Ooi W; Cole DE
    Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.